Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Authenticated data presented in the Respiratory Drugs market report is based on findings of extensive primary and secondary research ...

Cholinergic drugs (acetylcholine and methacholine ... Tiotropium, the first-choice long-acting bronchodilator in COPD, has been studied in severe asthmatics and in COPD patients with a history ...

Topline results from the groundbreaking Salford Lung Study are encouraging for GSK's new respiratory drug ... COPD were randomised 1:1 to receive FF/VI 100/25mcg, with or without a long-acting ...

In today’s fast-paced world, respiratory issues have become increasingly common, affecting individuals of all ages. Whether it’s due to environmental pollutants, allergens, or chronic conditions like ...

Independent investment company Breakthrough Victoria is investing $800,000 in Diag-Nose.io Medical (DNM), a Melbourne based ...

We recently published a list of 12 Best Depressed Stocks to Invest in Now. In this article, we are going to take a look at ...

Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Ra Monoclonal Antibody MG-K10 . SHENZHEN, CHINA, Jan 24, 2025 - (ACN News ...

Anti-IL-4Rα monoclonal antibodies are among the best-selling biologics in this field. MG-K10 is an innovative long-acting anti-IL-4Rα humanizedmonoclonal antibody that simultaneously blocks the ...

GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...